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Abstract
Background: Elderly patients become more important in oncology. In this group, personalized treatment
approaches taking into account survival prognoses and comorbidities play a major role. Predictive instruments are
necessary to estimate the survival of elderly cancer patients. The importance of separate instruments for different
tumor entities has been recognized. In this study, an instrument was generated to estimate the survival of elderly
patients developing metastatic spinal cord compression (MSCC) from breast cancer.
Methods: In 218 elderly patients (age ≥65 years) irradiated for MSCC from breast cancer, nine factors were
evaluated for survival: fractionation regimen, age, time from breast cancer diagnosis to RT of MSCC, visceral
metastases, other bone metastases, time developing motor deficits, pre-radiotherapy ambulatory status, number of
involved vertebrae, and Eastern Cooperative Oncology Group (ECOG) performance score. Factors significantly
associated with survival in the Cox regression analysis were included in the prognostic instrument. Scores for each
factor were calculated by dividing the 6-months survival rates by 10. The sums of these scores represented the
patients’ scores.
Results: On multivariate analyses, visceral metastases (p < 0.001), time developing motor deficits (p < 0.001),
ambulatory status (p < 0.001), number of involved vertebrae (p = 0.032), and ECOG performance score (p < 0.001)
were significant and included in the prognostic instrument. Based on the patients’ scores, three groups were
designed: 18–27 points, 28–39 points and 40–42 points. Six-months survival rates were 4, 62 and 100 %,
respectively (p < 0.001).
Conclusions: This new instrument contributes to personalized treatment in elderly patients with MSCC from breast
cancer by predicting an individual patient’s survival prognosis.
Background
Due to demographic changes, the proportion of elderly
patients is constantly increasing in many countries.
This is also true for patients requiring oncologic treat-
ment. Therefore, these cancer patients need particular
attention in terms of tailored treatment regimens taking
into account an individual patient’s performance status,
comorbidities and survival prognosis [1–4]. The latter
can be estimated with applying predictive instruments.
Due to improved medical support and treatment of
non-oncologic diseases in many countries worldwide,
more elderly cancer patients live longer. Since the risk
of developing metastases increases with lifetime, the
numbers of patients with metastases are growing. A
considerable number of these patients present with
metastatic spinal cord compression (MSCC), which can
occur in up to 10 % of all adult cancer patients [5, 6].
Therefore, elderly patients with MSCC need more
attention, and personalized treatment is very important.
In order to optimize such personalized approaches, the
patients’ survival prognoses must be considered. There-
fore, it is mandatory to have predictive instruments
available that are specifically designed for elderly pa-
tients. A survival score for elderly patients with MSCC
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has already been created [7]. However, that score has
been developed in a cohort of patients with MSCC
from many different primary tumor types. It is already
recognized that primary tumor types differ with respect
to tumor biology, metastatic patterns and prognoses.
Therefore, separate scores have been created for several
tumor entities [8–12]. However, these scores did not
consider the special characteristics of elderly cancer pa-
tients. Therefore, instruments predicting survival are
required for elderly patients that focus on a single pri-
mary tumor type. In the current study, such an instru-
ment has been developed particularly for elderly
patients with MSCC from breast cancer. This new in-
strument will contribute to further optimization of per-
sonalized treatment of elderly breast cancer patients.
Patients and methods
Two-hundred-and-eighteen elderly (age: 65 years or older)
patients with MSCC from breast cancer were included in
this retrospective study, which was approved by the local
ethic committee. The fractionation regimen (1 × 8 Gy vs.
5 × 4 Gy vs. 10 × 3 Gy vs. 15 × 2.5 Gy vs. 20 × 2 Gy) plus
eight additional factors were evaluated with respect to
potential associations with survival. These additional fac-
tors were age (≤73 vs. ≥74 years, median age 73 years),
time from breast cancer diagnosis to RT of MSCC (≤15
vs. >15 months), presence of visceral metastases prior to
RT (no vs. yes), presence of other bone metastases prior
to RT (no vs. yes), time developing motor deficits prior to
the start of RT (1–7 vs. 8–14 vs. <14 days), ambulatory
status prior to RT (no vs. yes), number of involved verte-
brae (1–3 vs. ≥4), and Eastern Cooperative Oncology
Group (ECOG) performance score (1–2 vs. 3 vs. 4). Activ-
ities of daily living (ADL) were not added as a potential
prognostic factor, since the ECOG performance score
considers this aspect. Therefore, the addition of a score of
ADL would have introduced confounding variables and
redundant information. This applies also to the factor co-
morbidity. In the Charlson Comorbidity Index, metastatic
cancer, which all of the patients included in our score
were suffering from, was given the highest score [13].
Hemiplegia was also an important comorbidity in the
Charlson Index, which is more or less reflected by ambu-
latory status (weakness of the legs, paraplegia) in our sur-
vival score.
Associations of the nine factors with survival were ini-
tially investigated in a univariate manner with the
Kaplan-Meier method and the log rank test [14]. Those
factors that achieved significance (p < 0.05) were subse-
quently analyzed for independence with the Cox regres-
sion analysis. Since pre-RT ambulatory status and
performance status can be considered confounding vari-
ables, two Cox regression analyses were performed, one
including the ambulatory status and one including the
performance status. The factors, which remained signifi-
cantly associated with survival also in the Cox regres-
sion, were included in the prognostic instrument. The
score for each factor was calculated by dividing the cor-
responding 6-months survival rates by 10. The sum of
these score scores represented the score for a patient.
Results
In the univariate analysis, survival was positively influ-
enced by absence of visceral metastases (p < 0.001),
absence of other bone metastases (p < 0.001), slower
development of motor deficits before the start of RT
(p < 0.001), ambulatory status before RT (p < 0.001),
involvement of only 1–3 vertebrae (p < 0.001), and an
ECOG performance score of 1–2 (p < 0.001). The re-
sults of the univariate analyses are summarized in
Table 1. In the subsequent Cox regression analyses,
visceral metastases (p < 0.001), time developing motor
deficits before the start of RT (p < 0.001), ambulatory
status before RT (p < 0.001), number of involved vertebrae
(p = 0.032), and the ECOG performance score (p < 0.001)
maintained significance (Table 2). These five factors were
included in the prognostic instrument for prediction of
survival (Table 3). The sum scores for the patients ranged
between 18 and 42 points. The 6-months survival rates re-
lated to these points are presented in Fig. 1. Taking into
account these survival rates, three survival groups were
designed, 18–27 points (group A), 28–39 points (group B)
and 40–42 points (group C). The 6-months survival rates
of these three groups were 4, 62 and 100 %, respect-
ively (p < 0.001, Fig. 2). The p-values for the compari-
sons of group A vs. group B and group B vs. group C
were p < 0.001 and p = 0.003, respectively.
Discussion
Elderly cancer patients are becoming more and more
important, since there proportions and numbers are
constantly increasing. In comparison to younger pa-
tients, elderly patients are different. They generally have
a poorer performance status, a greater comorbidity
index, a worse immune system, and a shorter survival.
Therefore, when treating these patients, specific pre-
cautions are mandatory. In order to provide the best
possible treatment for elderly cancer patients, very per-
sonalized approaches are needed. Such personalization
should consider an individual patient’s remaining life-
time, which can be estimated with the help of predict-
ive instruments. Because primary tumors are different,
each tumor requires separate prognostic tools. In this
study, we have created a scoring system to properly es-
timate the survival of elderly patients with MSCC from
breast cancer. According to a recursive partitioning analysis
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for another metastatic situation, brain metastases, “elderly”
patients were defined 65 years or older [15].
The present study identified five factors that were
independent predictors of survival, visceral metasta-
ses, time developing motor deficits, ambulatory status,
number of involved vertebrae (p = 0.032), and ECOG
performance score. These five factors were included in
the predictive instrument. When compared to the
survival score developed in elderly patients with
MSCC from different primary tumors, the independ-
ent factors of the present instrument were different
[7]. In the previous scoring system, eight factors were
independently associated with survival including age,
performance status, tumor entity, pre-RT ambulatory
status, other bone metastases, visceral metastases,
interval from cancer diagnosis to radiotherapy of
MSCC, and time developing motor deficits prior to
RT. In comparison to the new score for elderly pa-
tients with MSCC from breast cancer, four additional
factors were predictive for survival in that previous
score. The number of involved vertebrae was signifi-
cant in the new but not in the previous score. These
differences demonstrate that each tumor entity must
be considered separately and requires separate scoring
systems. The independent prognostic factors in this
study of elderly patients with MSCC from breast can-
cer also differed from the predictors of survival of an-
other previous score created in patients with MSCC
from breast cancer of any age [11]. Independent
factors in that previous score included performance
status, ambulatory status, other bone metastases, vis-
ceral metastases, interval from cancer diagnosis to
radiotherapy of MSCC and time developing motor
deficits, not the number of involved vertebrae. These
differences support the need for separate scores for
elderly cancer patients.
In the present study, three predictive groups with
significantly different survival prognoses were identi-
fied: 18–27 points (group A), 28–39 points (group B)
Table 1 Impact of the investigated factors on survival
(univariate analysis)
At 6 months At 12 months P
Age
≤ 73 years (N = 118) 69 57
≥ 74 years (N = 100) 70 53 0.63
Interval from breast cancer
diagnosis to RT of MSCC
≤ 15 months (N = 56) 64 46
> 15 months (N = 162) 71 58 0.23
Visceral metastases at the
time of RT
No (N = 117) 88 78
Yes (N = 101) 48 28 <0.001
Other bone metastases at
the time of RT
No (N = 79) 82 65
Yes (N = 139) 62 50 <0.001
Time developing motor
deficits prior to RT
1–7 days (N = 48) 33 6
8–14 days (N = 70) 73 61
> 14 days (N = 110) 83 70 <0.001
Ambulatory status prior to RT
Not ambulatory (N = 66) 41 28
Ambulatory (N = 152) 82 68 <0.001
Involved vertebrae (N)
1–3 (N = 127) 79 66
≥ 4 (N = 91) 56 40 <0.001
ECOG Performance status
1–2 (N = 120) 87 73
3 (N = 86) 55 38
4 (N = 12) 0 0 <0.001
Fractionation regimen
1 × 8 Gy (N = 26) 77 49
5 × 4 Gy (N = 59) 66 58
10 × 3 Gy (N = 72) 67 53
15 × 2.5 Gy (N = 20) 65 65
20 × 2 Gy (N = 41) 76 63 0.78
Table 2 Cox regression analysis of the factors that were







the time of RT
no vs. yes 5.42 3.34 – 9.05 <0.001
Other bone metastases
at the time of RT
no vs. yes 1.35 0.80 – 2.27 0.26
Time developing motor
deficits prior to RT
> 14 days vs. 8–14 days
vs. 1–7 days
1.68 1.30 – 2.17 <0.001
Ambulatory status prior to RT
ambulatory vs. not
ambulatory
2.34 1.56 – 3.51 <0001
Involved vertebrae (N)
1–3 vs. ≥ 4 1.18 1.01 – 1.37 0.032
ECOG Performance status
1–2 vs. 3 vs. 4 2.40 1.64 – 3.53 <0.001
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and 40–42 points (group C). In group A, only 4 % of
the patients survived at least 6 months. To avoid that
these patients spend unnecessarily too much of their
very limited life time with treatment, they should be
treated with single-fraction RT such as 1 × 8 Gy or
multi-fraction short-course RT such as 5 × 4 Gy in one
week. These fractionation regimens are not inferior to
longer-course RT programs with respect to functional
outcomes [16]. Patients of group B have an intermedi-
ate survival prognosis and can, therefore, be consid-
ered appropriate candidates for the worldwide most
commonly used fractionation regimen, 10 × 3 Gy in
two weeks, because 10 × 3 Gy results in better local
control of MSCC than single-fraction RT with 1 × 8 Gy
or short-course RT with 5 × 4 Gy in one week [17, 18].
Since patients of group C have a much more favorable
survival prognosis with a 6.months survival probability
of 100 %, these patients should receive longer-course
RT with total doses greater than 30 Gy. In a previous
study of patients with MSCC from different tumor
types and a favorable survival prognosis, doses beyond
30 Gy resulted in significantly better local control of
MSCC, progression-free survival and overall survival
when compared to 10 × 3 Gy [19]. Selected patients of
the prognostic groups B and C may be considered for
decompressive surgery in addition to conventional
radiotherapy or for stereotactic body radiation therapy
instead of conventional RT, preferably within clinical
trials [20–22].
In conclusion, this new predictive instrument con-
tributes significantly to proper estimation of the sur-
vival of elderly patients with MSCC from breast
cancer, and facilitates the administration of personal-
ized treatment regimens in this particular group of
cancer patients.
Table 3 Six-months survival rates of the independent





Visceral metastases at the time of RT
No (N = 117) 88 9
Yes (N = 101) 48 5
Time developing motor
deficits prior to RT
1–7 days (N = 48) 33 3
8–14 days (N = 70) 73 7
> 14 days (N = 110) 83 8
Ambulatory status prior to RT
Not ambulatory (N = 66) 41 4
Ambulatory (N = 152) 82 8
Involved vertebrae (N)
1–3 (N = 127) 79 8
≥ 4 (N = 91) 56 6
ECOG Performance status
1–2 (N = 120) 87 9
3 (N = 86) 55 6
4 (N = 12) 0 0
Fig. 1 Sum scores for each patient and the corresponding 6-months survival rates
Fig. 2 Kaplan-Meier curves for survival of the three prognostic
groups A (18–27 points), B (28–39 points) and C (40–42 points)
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